Evidence map›Paper›PMID 36834849›Full record

ArticleInternational journal of molecular sciences2023

Thymosin Beta 4 Inhibits LPS and ATP-Induced Hepatic Stellate Cells via the Regulation of Multiple Signaling Pathways.

Jihye Choi, Yunsang Cho, Hwal Choi, Sangmin Lee, Hyeju Han, Jeonghyeon Lee, Jungkee Kwon

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. [Thymosin β4 inhibits pyroptosis in BV2 microglial cells: a mechanistic studyZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jihye ChoiDepartment of Laboratory Animal Medicine, College of Veterinary Medicine, Jeonbuk National University, Iksan 54596, Republic of Korea.ORCID 0000-0003-2959-5610
Yunsang ChoDepartment of Laboratory Animal Medicine, College of Veterinary Medicine, Jeonbuk National University, Iksan 54596, Republic of Korea.
Hwal ChoiDepartment of Laboratory Animal Medicine, College of Veterinary Medicine, Jeonbuk National University, Iksan 54596, Republic of Korea.
Sangmin LeeDepartment of Laboratory Animal Medicine, College of Veterinary Medicine, Jeonbuk National University, Iksan 54596, Republic of Korea.
Hyeju HanDepartment of Laboratory Animal Medicine, College of Veterinary Medicine, Jeonbuk National University, Iksan 54596, Republic of Korea.
Jeonghyeon LeeDepartment of Laboratory Animal Medicine, College of Veterinary Medicine, Jeonbuk National University, Iksan 54596, Republic of Korea.
Jungkee KwonDepartment of Laboratory Animal Medicine, College of Veterinary Medicine, Jeonbuk National University, Iksan 54596, Republic of Korea.
Jeonbuk National University · KR

Funding

Korean government NRF-2018R1D1A3B07044209
6 · The paper itself

Abstract

Risk signals are characteristic of many common inflammatory diseases and can function to activate nucleotide-binding oligomerization (NLR) family pyrin domain-containing 3 (NLRP3), the innate immune signal receptor in cytoplasm. The NLRP3 inflammasome plays an important role in the development of liver fibrosis. Activated NLRP3 nucleates the assembly of inflammasomes, leading to the secretion of interleukin (IL)-1β and IL-18, the activation of caspase-1, and the initiation of the inflammatory process. Therefore, it is essential to inhibit the activation of the NLRP3 inflammasome, which plays a vital role in the immune response and in initiating inflammation. RAW 264.7 and LX-2 cells were primed with lipopolysaccharide (LPS) for 4 h and subsequently stimulated for 30 min with 5 mM of adenosine 5'-triphosphate (ATP) to activate the NLRP3 inflammasome. Thymosin beta 4 (Tβ4) was supplemented to RAW264.7 and LX-2 cells 30 min before ATP was added. As a result, we investigated the effects of Tβ4 on the NLRP3 inflammasome. Tβ4 prevented LPS-induced NLRP3 priming by inhibiting NF-kB and JNK/p38 MAPK expression and the LPS and ATP-induced production of reactive oxygen species. Moreover, Tβ4 induced autophagy by controlling autophagy markers (LC3A/B and p62) through the inhibition of the PI3K/AKT/mTOR pathway. LPS combined with ATP significantly increased thee protein expression of inflammatory mediators and NLRP3 inflammasome markers. These events were remarkably suppressed by Tβ4. In conclusion, Tβ4 attenuated NLRP3 inflammasomes by inhibiting NLRP3 inflammasome-related proteins (NLRP3, ASC, IL-1β, and caspase-1). Our results indicate that Tβ4 attenuated the NLRP3 inflammasome through multiple signaling pathway regulations in macrophage and hepatic stellate cells. Therefore, based on the above findings, it is hypothesized that Tβ4 could be a potential inflammatory therapeutic agent targeting the NLRP3 inflammasome in hepatic fibrosis regulation.

Indexed as

InflammasomesThymosinAdenosine TriphosphateAnimalsCaspase 1Hepatic Stellate CellsHumansInterleukin-1betaLipopolysaccharidesMiceNLR Family, Pyrin Domain-Containing 3 ProteinPhosphatidylinositol 3-KinasesSignal TransductionThymosin beta(4)Adenosine TriphosphateCaspase 1InflammasomesInterleukin-1betaLipopolysaccharidesNLR Family, Pyrin Domain-Containing 3 ProteinPhosphatidylinositol 3-KinasesThymosinThymosin beta(4)autophagyNLRP3 inflammasomeThymosin beta 4

Identifiers

PMID36834849
PMCPMC9959661
OpenAlexW4319761569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.